Rufinamide, Serum
Use
Rufinamide is an antiepileptic drug used as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in children aged 4 years and older and for the treatment of focal seizures in adults and adolescents. Monitoring serum rufinamide concentrations helps assess compliance and adjust dosage in patients receiving drugs that interact pharmacokinetically with rufinamide, such as those inducing liver CYP3A4 enzymes. It is also useful for patients undergoing hemodialysis.
Special Instructions
If not ordering electronically, complete and send one of the following forms with the specimen: Therapeutics Test Request (T831) or Neurology Specialty Testing Client Test Request (T732).
Limitations
No significant cautionary statements provided. The test's accuracy may be impacted by improper specimen collection and handling, inappropriate test selection, and interfering substances not detailed in the cautions section.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 59323-6
- 59323-6
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Collect blood immediately before the next scheduled dose. For sustained-release formulations only, collect blood a minimum of 12 hours after the last dose. Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.
Causes for Rejection
Gross hemolysis: OK; Gross lipemia: OK; Gross icterus: OK
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 28 days |
| Refrigerated | 28 days |
| Frozen | 28 days |